254 related articles for article (PubMed ID: 31891780)
1. Nanotechnology, in silico and endocrine-based strategy for delivering paclitaxel and miRNA: Prospects for the therapeutic management of breast cancer.
Ansari MA; Thiruvengadam M; Farooqui Z; Rajakumar G; Sajid Jamal QM; Alzohairy MA; Almatroudi A; Alomary MN; Chung IM; Al-Suhaimi EA
Semin Cancer Biol; 2021 Feb; 69():109-128. PubMed ID: 31891780
[TBL] [Abstract][Full Text] [Related]
2. Nanotechnological based miRNA intervention in the therapeutic management of neuroblastoma.
Pottoo FH; Barkat MA; Harshita ; Ansari MA; Javed MN; Sajid Jamal QM; Kamal MA
Semin Cancer Biol; 2021 Feb; 69():100-108. PubMed ID: 31562954
[TBL] [Abstract][Full Text] [Related]
3. Reconstituted high density lipoprotein mediated targeted co-delivery of HZ08 and paclitaxel enhances the efficacy of paclitaxel in multidrug-resistant MCF-7 breast cancer cells.
Zhang F; Wang X; Xu X; Li M; Zhou J; Wang W
Eur J Pharm Sci; 2016 Sep; 92():11-21. PubMed ID: 27343697
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-155-5p promotes tumor progression and contributes to paclitaxel resistance via TP53INP1 in human breast cancer.
Li Y; Zhang L; Dong Z; Xu H; Yan L; Wang W; Yang Q; Chen C
Pathol Res Pract; 2021 Apr; 220():153405. PubMed ID: 33756128
[TBL] [Abstract][Full Text] [Related]
5. Enhanced apoptotic and anticancer potential of paclitaxel loaded biodegradable nanoparticles based on chitosan.
Gupta U; Sharma S; Khan I; Gothwal A; Sharma AK; Singh Y; Chourasia MK; Kumar V
Int J Biol Macromol; 2017 May; 98():810-819. PubMed ID: 28189791
[TBL] [Abstract][Full Text] [Related]
6. CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer.
Swaminathan SK; Roger E; Toti U; Niu L; Ohlfest JR; Panyam J
J Control Release; 2013 Nov; 171(3):280-7. PubMed ID: 23871962
[TBL] [Abstract][Full Text] [Related]
7. Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2.
Régina A; Demeule M; Ché C; Lavallée I; Poirier J; Gabathuler R; Béliveau R; Castaigne JP
Br J Pharmacol; 2008 Sep; 155(2):185-97. PubMed ID: 18574456
[TBL] [Abstract][Full Text] [Related]
8. Resistance to paclitaxel therapy is related with Bcl-2 expression through an estrogen receptor mediated pathway in breast cancer.
Tabuchi Y; Matsuoka J; Gunduz M; Imada T; Ono R; Ito M; Motoki T; Yamatsuji T; Shirakawa Y; Takaoka M; Haisa M; Tanaka N; Kurebayashi J; Jordan VC; Naomoto Y
Int J Oncol; 2009 Feb; 34(2):313-9. PubMed ID: 19148464
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel and di-fluorinated curcumin loaded in albumin nanoparticles for targeted synergistic combination therapy of ovarian and cervical cancers.
Gawde KA; Sau S; Tatiparti K; Kashaw SK; Mehrmohammadi M; Azmi AS; Iyer AK
Colloids Surf B Biointerfaces; 2018 Jul; 167():8-19. PubMed ID: 29625422
[TBL] [Abstract][Full Text] [Related]
10. N-peptide of vMIP-Ⅱ reverses paclitaxel-resistance by regulating miRNA-335 in breast cancer.
Wang Y; Wang H; Ding Y; Li Y; Chen S; Zhang L; Wu H; Zhou J; Duan K; Wang W; Chen C; Yang Q
Int J Oncol; 2017 Sep; 51(3):918-930. PubMed ID: 28731125
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
12. MicroRNAs and Long Noncoding RNAs as Novel Therapeutic Targets in Estrogen Receptor-Positive Breast and Ovarian Cancers.
Barwal TS; Sharma U; Bazala S; Singh I; Jain M; Prakash H; Shekhar S; Sandberg EN; Bishayee A; Jain A
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920789
[TBL] [Abstract][Full Text] [Related]
13. Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer.
Thomas FC; Taskar K; Rudraraju V; Goda S; Thorsheim HR; Gaasch JA; Mittapalli RK; Palmieri D; Steeg PS; Lockman PR; Smith QR
Pharm Res; 2009 Nov; 26(11):2486-94. PubMed ID: 19774344
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer.
Ward A; Shukla K; Balwierz A; Soons Z; König R; Sahin O; Wiemann S
J Pathol; 2014 Aug; 233(4):368-79. PubMed ID: 24752803
[TBL] [Abstract][Full Text] [Related]
15. Lin28 mediates paclitaxel resistance by modulating p21, Rb and Let-7a miRNA in breast cancer cells.
Lv K; Liu L; Wang L; Yu J; Liu X; Cheng Y; Dong M; Teng R; Wu L; Fu P; Deng W; Hu W; Teng L
PLoS One; 2012; 7(7):e40008. PubMed ID: 22808086
[TBL] [Abstract][Full Text] [Related]
16. NT21MP negatively regulates paclitaxel-resistant cells by targeting miR‑155‑3p and miR‑155-5p via the CXCR4 pathway in breast cancer.
Wang Y; Yan L; Zhang L; Xu H; Chen T; Li Y; Wang H; Chen S; Wang W; Chen C; Yang Q
Int J Oncol; 2018 Sep; 53(3):1043-1054. PubMed ID: 30015868
[TBL] [Abstract][Full Text] [Related]
17. DEAE-Dextran coated paclitaxel nanoparticles act as multifunctional nano system for intranuclear delivery to triple negative breast cancer through VEGF and NOTCH1 inhibition.
Bakrania AK; Variya BC; Rathod LV; Patel SS
Eur J Pharm Biopharm; 2018 Jan; 122():37-48. PubMed ID: 29031923
[TBL] [Abstract][Full Text] [Related]
18. Identification of miRNA Signature in Breast Cancer to Predict Neoadjuvant Chemotherapy Response.
Xing AY; Wang B; Li YH; Chen X; Wang YW; Liu HT; Gao P
Pathol Oncol Res; 2021; 27():1609753. PubMed ID: 34257614
[No Abstract] [Full Text] [Related]
19. A novel MAPK-microRNA signature is predictive of hormone-therapy resistance and poor outcome in ER-positive breast cancer.
Miller PC; Clarke J; Koru-Sengul T; Brinkman J; El-Ashry D
Clin Cancer Res; 2015 Jan; 21(2):373-85. PubMed ID: 25370469
[TBL] [Abstract][Full Text] [Related]
20. Enhanced drug-loading and therapeutic efficacy of hydrotropic oligomer-conjugated glycol chitosan nanoparticles for tumor-targeted paclitaxel delivery.
Koo H; Min KH; Lee SC; Park JH; Park K; Jeong SY; Choi K; Kwon IC; Kim K
J Control Release; 2013 Dec; 172(3):823-31. PubMed ID: 24035978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
